Halia Therapeutics Appoints Former Amgen Director of Global Regulatory Affairs, Lisa Shamon, Ph.D., as Vice President of Regulatory Affairs and Former Amgen Scientist, Xianne Leong Penny, Ph.D., as Senior Medical Director
SALT LAKE CITY, Nov. 16, 2023 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced the...
Halia Therapeutics Continued Support to Utah’s Industry Community Recognized by First Place at the Utah Business Innovation Awards
Halia Therapeutics has been awarded first place in the Medical & Health: MedTech category of the Utah Business Innovation Awards
Halia Therapeutics to Present at the 17th Annual Pain Therapeutics Summit
LEHI, Utah, Oct. 18, 2023 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced that Jared Bearss, MBA,...
Halia Therapeutics to Present at the 17th Annual PAINWeek Conference
Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced they will be presenting new data at the 17th Annual PAINWeek Conference on Thursday, September 7, at 5:30 p.m. PDT/8:30 p.m. EDT.
Halia plans two trials testing its anti-inflammatory lead candidate
The company plans to start two Phase II trials later this year, with a further Phase I trial planned for early 2024.
Halia Therapeutics Opens the Doors of its New Headquarters and Laboratory Facilities in Lehi, Utah
SALT LAKE CITY, Aug. 16, 2023 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases driven by chronic inflammation and neurodegeneration, today announced the opening of its new...
Halia Therapeutics Announces Completion of Enrollment for Phase I Clinical Trial of HT-6184
- Halia expects to release data from the Phase I trial in Q4 2023 SALT LAKE CITY, Aug. 7, 2023 /PRNewswire/ -- Halia Therapeutics, a clinical-stage biopharmaceutical company advancing innovative medicines to treat a broad range of diseases that are driven by chronic...
Halia Therapeutics Appoints Anya Neidig, MSN, RN, as Director of Clinical Operations
Halia is excited to announce that Anya Neidig, MSN, RN, has joined our clinical team as Director of Clinical Operations. Anya brings over 20 years of experience in patient care and will help advance our #NEK7 and #LRRK2 programs through multiple clinical trials in...
Halia Therapeutics Promotes Targeting the NLRP3 Inflammasome for Alzheimer’s Disease Treatment
SALT LAKE CITY (August 16, 2022) – Halia Therapeutics, the first biotechnology company to target NEK7 to block the assembly of the NLRP3 inflammasome complex, participated today in a fireside chat exploring approaches to innovate Alzheimer’s therapies at...
Halia Therapeutics Announces Poster Presentation at Alzheimer’s Association Int’l Conference 2022
SALT LAKE CITY (August 1, 2022) – Halia Therapeutics, a biotechnology company that has used a structure-based drug design strategy to discover a series of small molecule therapeutics targeting important mediators of inflammation, announced today that it will present a...
Contact Us
Corporate Headquarters
3900 N. Traverse Mountain Blvd., Suite 100
Lehi, Utah 84043
United States
info@haliatx.com | +1 (385) 355-4315